Weight-loss injections are now firmly in the public conversation. For many patients, they are no longer niche medical treatments but familiar names discussed online, in clinics and across social media.
That growing demand has also created space for something far more dangerous - unlicensed and illegally manufactured products being sold to people who may not fully understand the risks.
On 28 May 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) carried out a raid on a country estate near Northampton. Officers recovered around 12,000 doses of unlicensed weight-loss medicines, the largest seizure of its kind the agency has ever made. Two men were arrested.
Andy Morling, head of the MHRA's Criminal Enforcement Unit, put the danger plainly when describing illicit jabs to the BBC: "It's just you and a syringe full of risk."
For aesthetic practitioners, this is more than a news story. Patients may already be using these products. Others may ask for your opinion, or seek help after buying from an online seller or unlicensed provider. Knowing how to respond matters for patient safety, professional practice and your own protection.
The May 2026 raid was not an isolated event. In October 2025, the MHRA raided a warehouse on an industrial estate in Northampton, seizing 2,000 pre-filled injectable pens and £20,000 in cash. According to the agency, that site is believed to be the world's first illegal manufacturing facility for weight-loss jabs where criminals created their own brand, rather than counterfeiting a legitimate product.
The substances involved included tirzepatide and retatrutide. The distinction between them matters:
The MHRA has confirmed that the May 2026 raid is connected to seizures made in Lincolnshire and Nottingham in February 2026. All form part of an ongoing investigation into an organised criminal network.
In short, these are not minor regulatory lapses. They involve deliberate, large-scale criminal manufacture of products that patients are injecting into their bodies.
Demand for weight-loss injectables has grown quickly. Research from University College London found that around 1.6 million UK adults used these medicines in 2025, with most buying through private prescriptions.
Cost is likely to be one of the factors pushing some people towards unregulated sources. A monthly private prescription for tirzepatide can range from about £150 for a starter dose to more than £300 at higher doses. Cheaper online alternatives can appear attractive, especially where patients are under pressure to lose weight quickly or feel unable to access treatment through regulated routes.
The same UCL research found that around 15 per cent of those surveyed were either taking medication not licensed for weight loss or buying from unlicensed providers. Crucially, patients do not always tell their practitioner where their products came from.
Aesthetic practitioners are often trusted by patients when it comes to injectable treatments, appearance-related concerns and wider questions about safety. That trust is valuable, but it also means you may be asked about products that sit outside lawful or insured practice.
If a patient mentions a weight-loss product bought online, through social media or from an unlicensed provider, the safest approach is to stay calm, avoid judgment, and explain the risks clearly.
The key point is simple, with illicit injections, there may be no reliable way to know what the product contains, how it was made, whether it was stored correctly, or what does the patient is actually receiving.
As Dr Jamie Green, a Northampton GP, told the BBC, the concern with cheap alternatives is that buyers may be “getting something that’s not what it says on the tin”.
This is where careful, practical thinking matters. You may well be asked about a product a patient bought online or from an unlicensed source. Knowing how to respond protects both your patient and your practice.
Insurance cover is linked to lawful practice and the terms of your individual policy. In broad terms, cover is likely to depend on whether the treatment involves licensed medicines, prescribed lawfully, used appropriately and delivered within your scope of practice.
Administering, recommending or advising on unlicensed or illegally manufactured products may affect your cover. The exact position will depend on your policy wording and your individual circumstances.
If you are unsure where you stand, check your policy documents or speak to the Hamilton Fraser team if you are uncertain. This article is general guidance and should not be treated as legal advice.
It can help to agree on a simple approach within your clinic or practice, so you are prepared if a patient raises the subject.
You may want to explain that you cannot support the use of unlicensed or illegally supplied medicines, because there is no reliable way to verify their contents, quality, dose or safety.
You can also encourage the patient to speak to a registered medical professional, particularly if they are experiencing side effects of are unsure what they have taken.
The tone matters. Patients are more likely to be honest if they feel they can talk openly. A calm, practical conversation is more useful than a warning that makes them defensive or reluctant to share information.
Two MHRA tools are worth sharing:
A simple recap: stay within licensed, lawful practice, check your cover, and signpost patients to trusted sources.
It is easy to read about record seizures and feel uneasy. The more constructive view is that this enforcement activity shows the system working. The MHRA is identifying criminal networks, dismantling production sites and removing dangerous products from circulation. Each raid makes the landscape safer for the patients and practitioners doing things properly.
Hamilton Fraser has supported the cosmetic sector since 1996, as the first commercial provider of medical malpractice insurance for the industry. Our role is to help you stay informed, stay protected and focus on what you do best: delivering safe, legal treatments your patients can trust.
If you have any questions about how your cover applies to weight-loss treatments, speak to our team. We are here to help you navigate the details, so you can practise with clarity and confidence.
For 30 years, Hamilton Fraser has stood beside aesthetic practitioners, offering medical malpractice cover and practical support that helps you work with confidence. As the picture around weight-loss injectables continues to shift, we will keep you informed of what matters and how it affects your practice. If you would like to talk through your cover or simply want clarity on where you stand, our team is on hand to help. Get in touch today and let us help you stay protected, so you can focus on delivering safe, legal treatments your patients trust.
